MannKind - MNKD Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month price targets for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 28.2% from the stock's current price.
View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts.

MannKind's stock was trading at $4.37 at the beginning of the year. Since then, MNKD shares have increased by 7.1% and is now trading at $4.68.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MNKD earnings forecast.

MannKind Co. (NASDAQ:MNKD) posted its earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company had revenue of $32.83 million for the quarter, compared to analysts' expectations of $25 million. The firm's quarterly revenue was up 47.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.04) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (7.92%), BlackRock Inc. (7.70%), Vanguard Group Inc. (4.98%), Emerald Advisers LLC (1.49%), Polar Asset Management Partners Inc. (0.69%) and Emerald Mutual Fund Advisers Trust (0.70%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends.

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MNKD stock can currently be purchased for approximately $4.68.

MannKind (NASDAQ:MNKD) has a market capitalization of $1.23 billion and generates $75.44 million in revenue each year. The biopharmaceutical company earns $-80,930,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

The company employs 348 workers across the globe.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.